Search
Semaglutide Treatment Options in Omaha, NE
A collection of 17 research studies where Semaglutide is the interventional treatment. These studies are located in the Omaha, NE. Semaglutide is used for conditions such as Diabetes Mellitus, Type 2, Obesity and Diabetes.
13 - 17 of 17
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Therapy
Unique Treatment for High Blood Pressure
Worried about high blood pressure? Think beyond typical high blood pressure treatments.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
Conditions:
High Blood Pressure
High Blood Pressure (& [Essential Hypertension])
High Blood Pressure (Hypertension).
Hypertension
Essential Hypertension
Featured Offer
Join Thousands Waiting for Retatrutide
Retatrutide could change the weight loss landscape. Unlike semaglutide or tirzepatide, it activates three hormone receptors simultaneously — and early data shows it:
✅ Outpaced existing GLP-1 medications for weight loss in clinical trials
✅ Improved blood sugar, blood pressure, and cholesterol beyond weight loss alone
✅ Delivered results with a simple once-weekly injection
✅ Now in Phase 3 trials with FDA submission expected in the next 1–2 years
Join the waiting list. One email when it launches — that's it.
✅ Outpaced existing GLP-1 medications for weight loss in clinical trials
✅ Improved blood sugar, blood pressure, and cholesterol beyond weight loss alone
✅ Delivered results with a simple once-weekly injection
✅ Now in Phase 3 trials with FDA submission expected in the next 1–2 years
Join the waiting list. One email when it launches — that's it.
Conditions:
Weight Loss
Featured Offer
Discover Affordable Semaglutide Providers
We Checked the Checkout Page on Every Semaglutide Provider. Here's What We Found.
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
Conditions:
Weight Loss
Morbid Obesity
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Completed
This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants taking "dummy" medicine. In addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what you can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which tre... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2021
Locations: Novo Nordisk Investigational Site, Omaha, Nebraska
Conditions: Metabolism and Nutrition Disorder, Overweight or Obesity
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
Completed
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/15/2021
Locations: Novo Nordisk Investigational Site, Omaha, Nebraska
Conditions: Hepatobiliary Disorders, Non-alcoholic Steatohepatitis
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
Completed
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2020
Locations: Novo Nordisk Investigational Site, Omaha, Nebraska
Conditions: Diabetes, Diabetes Mellitus, Type 2
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
Completed
This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the accrual of major adverse cardiovascular events (MACE) in this trial and the remaining research programme. The incidence of MACE will be monitored throughout the trial which will be terminated according to plan when pre-specified stopp... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/20/2019
Locations: Novo Nordisk Investigational Site, Omaha, Nebraska +1 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
Completed
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2019
Locations: Novo Nordisk Investigational Site, Omaha, Nebraska
Conditions: Diabetes, Diabetes Mellitus, Type 2
13 - 17 of 17